Fly News Breaks for March 3, 2015
PCRX
Mar 3, 2015 | 08:09 EDT
Canaccord lowered its price target on Pacira to $128 from $163 following the company's receipt of a complete response letter from the FDA. However, the firm believes the company's P3 data is good with its primary endpoint achieved and they believe the letter is looking at something other than the test results. Canaccord reiterated its Buy rating on Pacira shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX